It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Heart failure is the final common stage of most cardiopathies. Cardiomyocytes (CM) connect with others via their extremities by intercalated disk protein complexes. This planar and directional organization of myocytes is crucial for mechanical coupling and anisotropic conduction of the electric signal in the heart. One of the hallmarks of heart failure is alterations in the contact sites between CM. Yet no factor on its own is known to coordinate CM polarized organization. We have previously shown that PDZRN3, an ubiquitine ligase E3 expressed in various tissues including the heart, mediates a branch of the Planar cell polarity (PCP) signaling involved in tissue patterning, instructing cell polarity and cell polar organization within a tissue. PDZRN3 is expressed in the embryonic mouse heart then its expression dropped significantly postnatally corresponding with heart maturation and CM polarized elongation. A moderate CM overexpression of Pdzrn3 (Pdzrn3 OE) during the first week of life, induced a severe eccentric hypertrophic phenotype with heart failure. In models of pressure-overload stress heart failure, CM-specific Pdzrn3 knockout showed complete protection against degradation of heart function. We reported that Pdzrn3 signaling induced PKC ζ expression, c-Jun nuclear translocation and a reduced nuclear ß catenin level, consistent markers of the planar non-canonical Wnt signaling in CM. We then show that subcellular localization (intercalated disk) of junction proteins as Cx43, ZO1 and Desmoglein 2 was altered in Pdzrn3 OE mice, which provides a molecular explanation for impaired CM polarization in these mice. Our results reveal a novel signaling pathway that controls a genetic program essential for heart maturation and maintenance of overall geometry, as well as the contractile function of CM, and implicates PDZRN3 as a potential therapeutic target for the prevention of human heart failure.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Univ. Bordeaux, Inserm, UMR1034, Biology of Cardiovascular Diseases, Pessac, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)
2 Université Pierre et Marie Curie, Sorbonne University, INSERM UMR_S1166, Faculté de Médecine, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657)
3 Univ. Bordeaux, Inserm, UMR1034, Biology of Cardiovascular Diseases, Pessac, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); CHU de Bordeaux, Service de Biochimie Clinique, Bordeaux, France (GRID:grid.42399.35) (ISNI:0000 0004 0593 7118)
4 Univ. Bordeaux, Inserm, UMR1034, Biology of Cardiovascular Diseases, Pessac, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); CHU de Bordeaux, Service des Maladies Cardiaques et Vasculaires, Bordeaux, France (GRID:grid.42399.35) (ISNI:0000 0004 0593 7118)